コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 -51 mL/h with placebo and 110+/-56 mL/h with nesiritide.
2 will permit effective and appropriate use of nesiritide.
3 pamine (2 microg/kg per minute) nor low-dose nesiritide (0.005 mug/kg per minute without bolus) enhan
5 short-term outcome data from patients given nesiritide (0.015 or 0.03 microg/kg per min) with a subg
6 = .49) or on the change in cystatin C level (nesiritide, 0.07 mg/L; 95% CI, 0.01-0.13 vs placebo, 0.1
7 .1% and 12.8%, respectively; odds ratio with nesiritide 1.12; confidence interval, 0.95-1.32; P=0.19)
8 nts then received an intravenous infusion of nesiritide (2 microg/kg bolus followed by 0.01 microg/kg
10 t of the hospital within 30 days of surgery (nesiritide, 20 [minimum to maximum, 0-24]; milrinone, 18
12 t effect on 72-hour cumulative urine volume (nesiritide, 8574 mL; 95% CI, 8014-9134 vs placebo, 8296
14 otrope-based controls, respectively), as did nesiritide administered at any dose up to 0.06 microg x
15 This study was designed to determine whether nesiritide, administered for acute decompensated congest
16 rine output was 2,280 (1,550, 3,280) ml with nesiritide and 2,200 (1,550, 3,200) ml with placebo (p =
17 lantation, but intraoperatively the doses of nesiritide and anesthetics must be adjusted because of a
18 HF (Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure), 7,141 patie
22 on during hospitalization was similar in the nesiritide and placebo group (14.1% and 12.8%, respectiv
26 rmalities, and use of recombinant human BNP (nesiritide) and vasopeptidase inhibitors to treat heart
27 ritide) and B-type natriuretic peptide (BNP; nesiritide) are used to treat congestive heart failure.
41 tion, neither low-dose dopamine nor low-dose nesiritide enhanced decongestion or improved renal funct
44 receptor blockers for chronic heart failure, nesiritide for acute heart failure, and cytochrome P-450
47 rom any cause within 30 days was 9.4% in the nesiritide group versus 10.1% in the placebo group (abso
48 ontrast, renal function was preserved in the nesiritide group with no significant change in estimated
50 end toward decreased readmissions in the two nesiritide groups (8% and 11%, respectively, vs. 20% in
53 ts who received intravenous nitroglycerin or nesiritide had lower in-hospital mortality than those tr
54 le-blind, placebo-controlled clinical trial, nesiritide had no impact on renal function in patients w
60 this study was to further define the role of nesiritide (human b-type natriuretic peptide) in the the
62 with decompensated congestive heart failure, nesiritide improves hemodynamic function and clinical st
63 for use of nitroprusside, nitroglycerin, or nesiritide in addition to diuretics to achieve hemodynam
65 rom Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF), w
66 (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure [ASCEND-HF]; N
68 HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial randomi
74 addition, any patient admitted who received nesiritide in the absence of a primary or secondary hear
80 ed to double-blind treatment with placebo or nesiritide (infused at a rate of 0.015 or 0.030 microg p
83 effect of dopamine (interaction P=0.001) and nesiritide (interaction P=0.039) on urine volume varied
87 hat perioperative administration of low dose nesiritide is biologically active and decreases plasma c
89 ng the potential renal-preserving effects of nesiritide is mixed, and further studies on the efficacy
92 od and Drug Administration-approved doses of nesiritide (< or =0.03 microg x kg(-1) x min(-1)) signif
93 s suggest that low-dose dopamine or low-dose nesiritide may enhance decongestion and preserve renal f
95 , and renal effects of natriuretic peptides, nesiritide might be useful in the management of patients
96 pose of this study was to determine the role nesiritide might play in patients with left ventricular
97 jects, 35, 36, and 35 were randomized to the nesiritide, milrinone, and placebo groups, respectively,
98 es in which patients received nitroglycerin, nesiritide, milrinone, or dobutamine were identified and
101 andomized to placebo (n=20) or i.v. low dose nesiritide (n=20; 0.005 microg/Kg/min) for 24 hours star
102 sustained beneficial hemodynamic effects of nesiritide observed in this study support its use as a f
104 spital hypotension included randomization to nesiritide (odds ratio, 1.98; 95% confidence interval [C
105 e also tested for treatment interaction with nesiritide on 30-day outcomes and the association betwee
108 results have been reported on the effects of nesiritide on renal function in patients with acute deco
109 Our purpose was to evaluate the impact of nesiritide on renal function in patients with acute deco
110 there was no effect of low-dose dopamine or nesiritide on secondary end points reflective of deconge
113 regression models to identify the impact of nesiritide on urine output and the factors associated wi
115 mpared with placebo, empirical perioperative nesiritide or milrinone infusions are not associated wit
116 We sought to determine whether empirical nesiritide or milrinone would improve the early postoper
117 1 patients were randomized to receive either nesiritide or placebo and creatinine was recorded in 570
118 rt failure (ADHF) were randomized to receive nesiritide or placebo for 24 to 168 h, in addition to st
119 d with acute heart failure to receive either nesiritide or placebo for 24 to 168 hours in addition to
122 ith anticipated use of CPB to receive either nesiritide or placebo, in addition to usual care, for 24
126 re between January and August 2001 (prior to nesiritide release) and January 2004 to December 2005 (b
131 us, dyspnea, and fatigue were sustained with nesiritide therapy for up to seven days and were similar
135 nine and blood urea nitrogen were similar in nesiritide-treated and placebo-treated patients (P=0.20
139 f death from any cause at 30 days (3.6% with nesiritide vs. 4.0% with placebo; absolute difference, -
146 one or placebo, patients assigned to receive nesiritide would have improved early postoperative outco
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。